Abatacept in biologic-naive patients and TNF inadequate responders: clinical data in focus
- 27 June 2008
- journal article
- review article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 24 (8) , 2283-2294
Abstract
(2008). Abatacept in biologic-naive patients and TNF inadequate responders: clinical data in focus. Current Medical Research and Opinion: Vol. 24, No. 8, pp. 2283-2294. doi: 10.1185/03007990802223129Keywords
This publication has 29 references indexed in Scilit:
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Annals of the Rheumatic Diseases, 2007
- Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled studyArthritis & Rheumatism, 2006
- Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trialArthritis & Rheumatism, 2005
- Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti–tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy studyArthritis & Rheumatism, 2005
- Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateArthritis & Rheumatism, 2004
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusionArthritis & Rheumatism, 2002
- Socio-economic consequences of rheumatoid arthritis in the first years of the disease.Rheumatology, 1999
- Rheumatoid arthritis and cancer riskEuropean Journal of Cancer, 1996